{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:28:21Z","timestamp":1790252901379,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.kint.2019.04.030","type":"journal-article","created":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T11:30:33Z","timestamp":1557919833000},"page":"193-201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"title":["Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease"],"prefix":"10.1016","volume":"97","author":[{"given":"Meghan E.","family":"Sise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald F.","family":"Chute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaa","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya I.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuni T.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nifasha","family":"Rusibamayila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Jean-Francois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda","family":"Raji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2019.04.030_bib1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1053\/j.gastro.2016.02.039","article-title":"Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2019.04.030_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2012.04.003","article-title":"Association of hepatitis C virus infection with risk of ESRD: a population-based study","volume":"60","author":"Su","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2019.04.030_bib3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/archinte.167.12.1271","article-title":"Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease","volume":"167","author":"Tsui","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2019.04.030_bib4","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.kint.2019.04.030_bib5","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2019.04.030_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1523-1755.2005.00080.x","article-title":"Relationship between hepatitis C and microalbuminuria: results from the NHANES III","volume":"67","author":"Liangpunsakul","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.030_bib7","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1111\/j.1523-1755.2004.00649.x","article-title":"Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS","volume":"65","author":"Fissell","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.030_bib8","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.030_bib9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.030_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.030_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2019.04.030_bib12","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"10.1016\/j.kint.2019.04.030_bib13","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2169\/internalmedicine.37.836","article-title":"Glomerulonephritis in autopsy cases with hepatitis C virus infection","volume":"37","author":"Arase","year":"1998","journal-title":"Intern Med"},{"key":"10.1016\/j.kint.2019.04.030_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7326\/0003-4819-144-10-200605160-00007","article-title":"Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation","volume":"144","author":"McGuire","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2019.04.030_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/ki.2008.107","article-title":"The risk of acute renal failure in patients with chronic kidney disease","volume":"74","author":"Hsu","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.030_bib16","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4\u20135 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2019.04.030_bib17","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2019.04.030_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","article-title":"Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection","volume":"6","author":"Satapathy","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.kint.2019.04.030_bib19","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1097\/MD.0000000000001334","article-title":"A\u00a0Taiwanese Nationwide cohort study shows interferon-based therapy for chronic hepatitis c reduces the risk of chronic kidney disease","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2019.04.030_bib20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.kint.2019.04.030_bib21","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/lt.23756","article-title":"Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease","volume":"20","author":"Bl\u00e9","year":"2014","journal-title":"Liver Transpl"},{"key":"10.1016\/j.kint.2019.04.030_bib22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of sofosbuvir-based hepatitis C virus therapy on kidney function in patients with CKD","volume":"12","author":"Sise","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2019.04.030_bib23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jcpt.12697","article-title":"Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: a Brazilian \"real-life\" study","volume":"43","author":"Medeiros","year":"2018","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.kint.2019.04.030_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2019.04.030_bib25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2019.04.030_bib26","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ki.2013.444","article-title":"Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward","volume":"85","author":"Levin","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2019.04.030_bib27","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute Dialysis Quality Initiative w. acute renal failure\u2014definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819305083?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253819305083?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:55:17Z","timestamp":1758761717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253819305083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0085253819305083"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.030","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2019.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}